Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus

Clinical Drug Investigation

Volumn 25, Issue 9, 2005, Pages 589-595

  Segal, Pesach ^a,b   Eliahou, Haskel E ^a,b   Petzinna, Dieter ^c   Neuser, Dieter ^c   Brückner, Andreas ^c   Spengler, Manfred ^c  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; ASPARTATE AMINOTRANSFERASE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LIPID; LIVER ENZYME; PLACEBO;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; KIDNEY DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METEORISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARAMETER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; SAMPLE SIZE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMPTOM;

EID: 25644435031     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200525090-00004     Document Type: Article

References (29)

1. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple thera-pies (UKPDS 49). JAMA 1999 Jun; 281 (21): 2005-12
2. Laube H. Acarbose: an update of its therapeutic use in diabetes treatment. Clin Drug Invest 2002; 22 (3): 141-56
3. Breuer H-WM. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. Int J Clin Pharmacol Ther 2003; 41 (10): 421-40
4. Hasche H, Mertes G, Bruns C, et al. Effects of acarbose treatment in type 2 diabetic patients under dietary training. A multicentre, double-blind, placebo-controlled, 2-year study. Diabetes Nutr Metab 1999; 12: 277-85
5. Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001; 52: 193-204
6. Chiasson J-L, Josse RG, Gomis R, et al. Acarbose for preven-tion of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002 Jun; 359: 2072-7
7. Chiasson J-L, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003 Jul; 290: 486-94
8. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-6
9. Stettler C, Mueller B, Diem P. What you always wanted to know about HbA1c [in German]. Schweiz Med Wochenschr 2000; 130: 993-1005
10. James TM, Davis JE, McDonald JM, et al. Comparison of hemoglobin A1c and hemoglobin A1 in diabetic patients. Clin Biochem 1981; 14 (1): 25-7
11. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conven-tional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 Sep; 352: 837-53
12. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-30
13. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000 Apr; 108 (6A): 15S-22S
14. Bayraktar M, Van Thiel DH, Adalar N. A comparison of acar-bose versus metformin as an adjuvant therapy in sulphonylurea-treated NIDDM patients. Diabetes Care 1996 Mar; 19: 252-4
15. May C. Efficacy and tolerability of stepwise increasing dosage of acarbose in patients with non-insulin-dependent diabetes mellitus (NIDDM), treated with sulfonylureas [in German]. Diabetes und Stoffwechsel 1995; 4: 3-8
16. Wilms B, Ruge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-con-trolled study. Diabet Med 1999; 16: 755-61
17. Costa B, Piñol C. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes Res Clin Pract 1997; 38: 33-40
18. Lam KSL, Tiu SC, Tsang MW, et al. Acarbose in NIDDM patients with poor control on conventional oral agents. Diabetes Care 1998 Jul; 21: 1154-8
19. Lin BJ, Wu H-P, Huang HS, et al. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas. J Diabetes Complications 2003; 17: 179-85
20. Chiasson J-L, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 1994; 121: 928-35
21. Bachmann W, Petzinna D, Raptis SA, et al. Long-term improvement of metabolic control by acarbose in type 2 diabetes patients poorly controlled with maximum sulfonylurea therapy. Clin Drug Invest 2003; 23 (10): 679-86
22. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UKPDS 44). Diabetes Care 1999 Jun; 22: 960-4
23. Adler AI, Stratton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000 Aug; 321: 412-9
24. Rosenthal JH, Mauersberger H. Effects on blood pressure of the α-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clin Drug Invest 2002; 22 (10): 695-701
25. Frantz S, Calvillo L, Tillmanns J, et al. Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the α-glucosidase inhibitor acarbose. FASEB J 2005 Apr; 19: 591-3
26. Ceriello A. New insights on oxidative stress and diabetic com-plications may lead to a 'causal' antioxidant therapy. Diabetes Care 2003 May; 26: 1589-96
27. Rudofsky Jr G, Reismann P, Schiekofer S, et al. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-κB activation in PBMCs. Horm Metab Res 2004; 36: 630-8
28. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 Aug; 321: 405-12
29. Bayer HealthCare. Glucobay®. Available from URL: http://www. glucobay.com [Accessed 2004; Aug 24]